| Authors: |
Pelton SI; Boston University School of Public Health, Boston, MA, USA. spelton@bu.edu.; Boston Medical Center, Boston, MA, USA. spelton@bu.edu.; Maxwell Finland Laboratory for Infectious Diseases, 670 Albany Street, 6th Floor, Boston, MA, 02118, USA. spelton@bu.edu., Shea KM; Boston University School of Public Health, Boston, MA, USA. kimshea@bu.edu., Farkouh RA; Pfizer Inc., Collegeville, PA, USA. rfarkouh@pfizer.com., Strutton DR; Pfizer Inc., Collegeville, PA, USA. dstrutto@jhsph.edu., Braun S; Xcenda GmbH, Hannover, Germany. sebastian.braun@xcenda.de., Jacob C; Xcenda GmbH, Hannover, Germany. christian.jacob@xcenda.de., Klok R; Pfizer bv, Capelle a/d IJssel, Netherlands. rogier.klok@pfizer.com., Gruen ES; Policy Analysis Inc. (PAI), Brookline, MA, USA. egruen@pai2.com., Weycker D; Policy Analysis Inc. (PAI), Brookline, MA, USA. dweycker@pai2.com. |